PIERCE GLENN 4
4 · Global Blood Therapeutics, Inc. · Filed Jun 16, 2022
Insider Transaction Report
Form 4
PIERCE GLENN
Director
Transactions
- Exercise/Conversion
Common Stock
2022-06-14+3,600→ 26,437 total - Exercise/Conversion
Restricted Stock Units
2022-06-14−3,600→ 0 totalFrom: 2022-06-14→ Common Stock (3,600 underlying) - Award
Stock Option (Right to Buy)
2022-06-14+5,600→ 5,600 totalExercise: $22.30Exp: 2032-06-13→ Common Stock (5,600 underlying) - Award
Restricted Stock Units
2022-06-14+3,600→ 3,600 total→ Common Stock (3,600 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The RSUs vested in a single installment on June 14, 2022.
- [F3]The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
- [F4]The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).